CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.
Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.
Be the leaders in regenerative medicine, helping people live longer and better through our innovative collagen technology.
Discover, develop and deliver collagen technology and regenerative-medicine products to improve and prolong lives.
Transforming curiosity into new concepts and products, to save lives and shape a better future.
Striving to combine exceptional multidisciplinary expertise with the rapid delivery of proven, best-in-class products & technologies.
Creating a corporate culture that motivates our people and gives us a sense of pride in our work.
Acting honestly, fairly and ethically, with full transparency.
Realizing the synergy of different people, ideas, interests and cultures in wide-ranging products and technologies.
Founder and Chief Scientist
Oded is a faculty member of the Hebrew University of Jerusalem and has accumulated extensive experience with plant molecular biology and protein engineering. He has authored more than 160 scientific publications and is the inventor of 46 patents. He received the Outstanding Scientist Polak Award in 2002, the 1999 and 2010 Kay Award for Innovative and Applied Research and the 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation. In addition to CollPlant, Oded is the scientific founder of nine companies, among them CBD-Technologies/FuturaGene, SP Nano Ltd., Melodea Ltd., Valentis Nanotech. Ltd. and Paulee CleanTec Ltd.
Chief Executive Officer
Yehiel is a seasoned executive in the biomedical field and brings over two decades of management experience in both high-tech and biotech companies. He joined CollPlant in 2010 and prior to this, Yehiel served as CEO and Co-founder of Regentis Biomaterials Ltd.; Vice-President of Business Development at ProChon BioTech Ltd.; Vice President of Marketing and Business Development at OrthoScan Technologies Ltd.; and Director of Business Development and Business Unit Manager at Kulicke and Soffa Industries, Inc. Yehiel holds a BSc and an MSc degree in Mechanical Engineering from the Technion-Israel Institute of Technology.
Deputy CEO & Chief Financial Officer
Eran is a veteran financial executive in the biotech and industrial sectors. He joined CollPlant in 2012 and prior to this, Eran served as the Chief Financial Officer of Tefron Ltd., a global industrial company traded on both the Tel Aviv Stock Exchange (TASE:TFRN) and on the OTCBB (OTC:TFRFF) in the U.S. He also served as Chief Financial Officer of Healthcare Technologies Ltd. (NASDAQ:HCTL), Gamida MedEquip and Gamida For Life, a group of companies specializing in the development, manufacturing and marketing of clinical diagnostic test kits worldwide and medical equipment and services to the biotech and high tech industries. Before Gamida, Eran served as a Senior Manager at Ernst & Young. Eran holds a BA in Accounting and Business Administration from the Tel Aviv College of Management and is a Certified Public Accountant.
Vice President of R&D
Nadav is an accomplished R&D Manager with specific experience in bio-surgery products. He joined CollPlant in 2014 and prior to this, Nadav served as an Associate Director and Manager of an R&D group at Omrix Biopharmaceuticals Ltd., a subsidiary of ETHICON Biosurgery, a Johnson & Johnson company. While at Omrix, Nadav led an international team developing hemostatic combination products and led base business support for production processes and products. Nadav holds a PhD from the Weizmann Institute of Science.
Chief Operations Officer
Ilana brought her extensive executive experience in managing operations as well as research and development processes in the biotechnology and pharmaceutical industries to CollPlant. She joined the company in 2015 and prior to this, Ilana served as COO at BioHarvest, an innovative botanical biotech company. Her previous positions included 14 years as an R&D and Product Manager at SERONO-InterPharm Laboratories, VP R&D and Operations at Procognia and Plant Manager at Omrix Biopharmaceuticals Ltd. In these positions, she was responsible for a wide range of operations activities including process development, production, logistics, technical support and packaging. Dr. Belzer gained vast experience in R&D management as well as GMP production of pharmaceutical products, business development projects and led the planning and construction of new production facilities. Ilana holds a Ph.D from the Tel Aviv University.
Vice President of Regulatory Affairs and Quality Assurance
Philippe brings over two decades of experience in Regulatory Affairs, Quality Assurance and Clinical Affairs in the international medical device industry. He joined CollPlant in 2011 and prior to this, Philippe served for 14 years as Director of RA/QA/CA at InterVascular Datascope (now Maquet-Getinge), a manufacturer of cardiovascular long-term implants. Philippe was also with 3M Medical, as Manager of Regulatory Affairs. Philippe holds a PharmD Degree from the University of Pharmacy in Marseille, France.
Dr. Pomerantz was appointed CollPlant’s Chairman of the board of directors in February 2020. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect, and a board member of Intec Pharma and VerImmune. Dr. Pomerantz served as Chairman of the board of directors of Seres Therapeutics in 2019, where he served as Chairman and CEO from June 2014 until January 2019. From 2011 to 2013, he was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc.
Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed twelve small and large molecular drugs approved world-wide in important diseases, including HIV, HCV, CMV, C. Diff, and tuberculosis.
Dr. Havron joined our board of directors in May 2016 bringing with him his extensive experience in the biotechnology sector. Since 2011, Dr. Havron has been serving as an external director at Kamada as well as being a member of their company audit and compensation committees. From 2005, Dr. Havron was the CEO and Director of PROLOR Biotech Inc. (NYSE MKT: PBTH; TASE: PROL) until it was acquired by OPKO Health Inc. in 2013. Dr. Havron also served as the Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to 2003. From 1987 to 1999, Dr. Havron was the Vice President Manufacturing and Process Development at BioTechnology General Ltd. which is currently a subsidiary of Ferring Pharmaceuticals. In 1980 he joined the founding team of Interpharm Laboratories Ltd. (a subsidiary of Merck Serono S.A.) and was Director of Research and Development until 1987. Dr. Havron holds a PhD in Bio-Organic Chemistry from the Weizmann Institute of Science and served as Research Fellow at Harvard Medical School between 1978-1980.
Gili Hart is a Biotech executive serving as OPKO Biologic’s General Manager since 2014. Dr. Hart brings extensive experience in managing critical global programs ranging from preclinical work through Phase 3 clinical trials. Dr. Hart has broad experience in global regulatory strategic planning and interactions and partnering deals with large-pharma, public company road shows and financing.
Dr. Hart served as VP of Pre-clinical and Clinical Pharmacology in PROLOR Biotech from 2013-2009 and before that as a Senior Director.
During the period from 2005-2007, Dr. Hart was a Research Fellow in the Immunology Department at the Weizmann Institute of Science in collaboration with Faculty of Immunobiology, Yale University’s School of Medicine. She received her PhD cum laude from the Weizmann Institute and also graduated summa cum laude from the Technion with a Biotechnology Engineering Degree.
Dr. Hart has published numerous papers and patents and in her scientific work, she focused on autoimmunity diseases as well as on B and T cells migration that can directly affect inflammation and immune conditions.
Dr. Elan Penn joined our Board of Directors in January 2018. Dr. Penn has served as CEO and Chairman of Penn Publishing Ltd. since 2001. From 2000 to 2001, Dr. Penn served as VP of Finance and Administration of A.I. Research and Development Ltd.
During the years 1998 through 2000, Dr. Penn served as CEO of Sivan Computer Training Company Ltd. From 1992 to 2000, Dr. Penn served as VP of Finance and Administration of Mashov Computers Ltd. From 1987 to 1991 and again from 1992 to 1997, Dr. Penn served as VP of Finance and Administration of Magic Software Enterprises Ltd. (NASDAQ: MGIC) and from 2005 to 2014 served as an External Director of Magic Software Enterprises Ltd. Dr. Penn previously served as a Director of Telkoor Power Supplies Ltd. (TASE: TLCR) and Nexgen Biofuels Ltd. (Formerly Healthcare Technologies Ltd.)(NASDAQ:NXGN).
Dr. Penn holds a BA degree in Economics from the Hebrew University of Jerusalem and PhD in Management Science from Imperial College, University of London.
Mr. Joseph Zarzewsky joined our Board of Directors in August 2019. Joseph Zarzewsky has served as the Vice President of Business Development at the Mitrelli Group (“Mitrelli”) since 2010. Mr. Zarzewsky has served as the Chairman of “SMAD”, a joint venture between Mitrelli and the Harbin Government, China, since 2011. Mr. Zarzewsky has also served as the Chairman of the Investment Committee of the Harbin Israel Fund since 2012, and as a member of the board of directors of Wize Pharma, Inc. (OTCQB: WIZP) since 2017. He has also previously served as the Vice President of marketing at Clal Insurance Enterprises Holdings Ltd. (TASE: CLIS) and as the Vice President of Marketing for the Israel Postal Authority. In addition, Mr. Zarzewsky has served as a director of Excellence Underwriter House Ltd. since 2007. In 2008, he was appointed as the Honorary Economic Advisor of the Harbin Government, China. In addition, in 2012, he was honored as an Honorary Citizen of Harbin, China. Mr. Zarzewsky holds an MA in Commercial Law from the University of Tel Aviv in collaboration with the University of California, Berkeley.
Unit Of Biochemistry, Technion Nobel Laureate in Chemistry 2004
Avram Hershko was born in 1937 in Hungary and emigrated with his family to Israel in 1950. He gained his MD (1965) and PhD (1969) from the Hebrew University- Hadassah Medical School of Jerusalem. After a post-doctoral fellowship at the University of California of San Francisco (1969-72), he joined the faculty of the Haifa Technion becoming professor in 1980. He is now Distinguished Professor in the Unit of Biochemistry in the B. Rappaport Faculty of Medicine of the Technion. His main research interests concern the mechanisms by which cellular proteins are degraded, a formerly neglected field of study. Hershko and his colleagues showed that cellular proteins are degraded by a highly selective system. This system tags proteins for destruction by linkage a protein called ubiquitin, which had previously been identified in many tissues, as the name suggests, but whose function was previously unknown. Subsequent work in Hershko's and many other laboratories has shown that the ubiquitin system has a vital role in controlling a wide range of cellular processes, such as the regulation of cell division, signal transduction and DNA repair. Abnormalities in the ubiquitin system result in diseases such as certain types of cancer. The full range of functions of the ubiquitin system in health and disease has still to be elucidated. Hershko was awarded the Nobel Prize in Chemistry (2004) jointly with his former PhD student Aaron Ciechanover and his colleague Irwin Rose. His many other honors include the Israel Prize for Biochemistry (1994), the Gairdner Award (1999), The Alfred P. Sloan Prize of the General Motors Cancer Research Foundation (2000), the Lasker Prize for Basic Medical Research (2000), the Wolf Prize for Medicine (2001) and the Louisa Gross Horwitz Award (2001). Hershko is a member of the Israel Academy of Sciences (2000) and a Foreign Associate of the US Academy of Sciences (2003).
Harvard School of Dental Medicine
Vicki Rosen is currently Professor and Chair, Department of Developmental Biology, Harvard University School of Dental Medicine where her research is focused on the formation, maintenance and regeneration musculoskeletal tissues. Prior to joining the faculty of medicine at Harvard, she was Director of Tissue Growth and Repair at Genetics Institute, Inc., where she was part of the research team that identified the bone morphogenetic protein (BMP) genes in 1988. She has 30 US patents and 3 US FDA approved products in the area of tissue regeneration. She received an honorary degree from Harvard University in 2001, was co-recipient of the ORS Kappa Delta Award for outstanding orthopedic research in 2008, and the ORS Marshall Urist Award for excellence in tissue engineering in 2009.
National University of Ireland, Galway
Abhay Pandit is the Director of a Science Foundation Ireland funded Strategic Research Cluster “Network of Excellence for Functional Biomaterials” (NFB) at the National University of Ireland, Galway. Prof Pandit research programme hosts several patented technology platforms associated with the development of implantable materials for clinical applications. Functionality to these forms is achieved through custom chemistries which facilitate the attachment of surface tethered moieties or encapsulated therapeutic factors including drugs, genes and other active agents. His research is currently funded by Science Foundation Ireland, Enterprise Ireland, Health Research Board, Dystrophic Epidermal Bullosa Research Association, 7th EU Framework, European Molecular Biology Organization and AO Foundation amongst others. He has generated research contracts from industry and government funding agencies totaling €17,229,006.40 in the last 7 years. He is the author of 2 patents with 9 other patent applications are pending. He has published 75 papers in high-impact factor publications including Trends in Biotechnology, Small, Biomaterials and Tissue Engineering and has authored 267 papers at both national and international conferences in the past eight years.
Abhay Pandit is a member of the editorial board of 8 journals including Biomaterials, European Cells and Materials and The Journal of Materials Science: Materials in Medicine. He also acts as a Referee for 42 journals in cognate areas. He is a Grant Panelist for 5 funding agencies including The Leverhulme Trust, The Academy of Finland’s Panel in Biomedical Engineering, and The Irish-US Fulbright Commission. He is a Grant Reviewer for 16 funding agencies including the 7th EU Framework, the UK’s Medical Research Council, the AO Foundation, the Welcome Trust, the Agency for Science, Technology and Research’s (A*STAR) Biomedical Research Council (BMRC), the Engineering and Physical Sciences Research Council (EPSRC), The Biotechnology and Biological Sciences Research Council (BBSRC), The UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) Research Grants, the Swiss National Science Foundation and the Dutch Burns Foundation. Prof. Pandit hosted the Tissue Engineering Regenerative Medicine International Society Conference – EU Meeting in 2010 and will host The European Society for Biomaterials Conference in 2011 – one of the few groups to host these prestigious conferences in consecutive years.
In addition for his contribution to the society at large he was recently elected on the board of TERMISEU Council. Abhay sees his role in the council as an active contributor to the strategic direction of TERMIS-EU. Specifically he sees a role in adding high value to the annual conference and developing a support base for young and upcoming researchers in the Society.
MD, Hospital for Special Surgery
Dr. Lane’s research interests include collagen metabolism, cartilage preservation and transplantation, bone regeneration and connective tissue injury and repair. Formal training included a chemistry undergraduate degree, graduating Magna Cum Laude from Columbia University and M.D. from Harvard University. In addition to clinical professorship posts, Dr. Lane has held numerous positions for on-going research in orthopaedics with the National Institute of Health and the American Academy of Orthopaedic Surgeons. He is presently Professor of Orthopaedic Surgery and Assistant Dean, Medical Students at Weill Cornell Medical College, New York. He is an Attending, Orthopaedic Surgery at Hospital for Special Surgery, New York. He has served as Chief of Bone Tumors at Memorial Sloan-Kettering Cancer Center, New York and Chairman of Orthopaedics at UCLA.
Dr. Lane has served as Chairman to many professional society functions and committees. His influence in orthopaedic research is evidenced by hundreds of publications, book chapters and scientific articles. In addition, Dr. Lane has contributed to orthopaedic knowledge as a frequent visiting professor and corporate consultant domestically and internationally.
MD MCh (Orth)
Consultant Orthopaedic, Shoulder and Elbow Surgeon. Professor and Chair of the Orthopaedic Surgery Research and Learning Centre - at Brunel University, West London. Director of the Reading Shoulder Unit, an international centre of excellence for shoulder and elbow surgery, Reading, United Kingdom. The unit is recognised worldwide, as a clinical, academic and research centre. Ofer Levy studied medicine at the Hebrew University and Hadassah School of Medicine, Jerusalem and his orthopaedic surgical training at Sheba Medical Centre, Israel. He is assistant editor, Journal of Shoulder and Elbow Surgery, On the Editorial board of the International Journal of Shoulder Surgery. Special External Examiner, the national university of Ireland and the Royal College of Surgeons in Ireland. Awarded UK national bronze clinical excellence award in 2006. Awarded the Kessel best research award of the British Elbow and Shoulder Society 2010. Member of the British and Israeli Orthopaedic associations. He is a founder member of the Israeli Shoulder and Elbow Society, a member of the European Society of Shoulder and Elbow Surgery and the British Elbow and Shoulder Society (BESS) and corresponding member of the American Shoulder and Elbow Society (ASES) - for outstanding contribution in the field. Organises international courses on shoulder surgery, for arthroscopic surgery and shoulder arthroplasty. He has published over 400 scientific papers and presentations, written chapters to books on shoulder surgery and invited to lecture worldwide.
Wake Forest Institute for Regenerative Medicine
Prof. Soker brings over 25 years of expertise in the areas of tissue engineering, stem cells, tissue scaffolds, cell differentiation and bioengineering to CollPlant. He currently serves as Professor of Regenerative Medicine and the Scientific Officer for WFIRM. Prof. Soker is an affiliated Professor of Cancer Biology, Physiology & Pharmacology, Biomedical Engineering and Surgical Sciences at the Wake Forest School of Medicine.
Prof. Soker received his Ph.D. from the Technion-Israel Institute for Technology and was a postdoctoral trainee in the Department of Surgical Research at the Boston Children’s Hospital and Harvard Medical School. Working with Michael Klagsbrum and the late Judah Folkman, Prof. Soker’s research focused on vascular biology, with emphasis on angiogenic growth factors and their receptors. Prof. Soker joined the Laboratory for Tissue Engineering and Cellular Therapies, under the leadership of Anthony Atala, and was promoted to Assistant Professor at Harvard Medical School. In 2004, Prof. Soker joined the Wake Forest School of Medicine at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina to launch WFIRM. He was promoted to Associate Professor in 2004 and has been a tenured professor since 2010. Prof. Soker has developed programs in neo-vascularization of bioengineered tissues, stem cell from different sources for tissue engineering in vitro and in vivo and tissue-derived extracellular matrices as scaffolds for whole organ bioengineering. Prof. Soker had published this technology for the engineering of organs and tissues including liver, kidney, pancreas, intestine, cornea and more.
Prof. Soker has authored more than 160 scientific publications and reviews and has contributed chapters to numerous books. Over the course of his distinguished career, he has been the recipient of many academic awards, and has received research grants from the National Institutes of Health and the Department of Defense, as well as numerous foundations and industry. Prof. Soker is a frequent and highly sought-after speaker at scientific meetings and conferences.